Alembic Pharmaceuticals Ltd (BOM:533573)
₹ 1029.25 -1.7 (-0.16%) Market Cap: 202.31 Bil Enterprise Value: 211.48 Bil PE Ratio: 31.31 PB Ratio: 4.14 GF Score: 91/100
Back to the Transcripts List

Q1 2025 Alembic Pharmaceuticals Ltd Earnings Call Transcript

Aug 08, 2024 / 10:30AM GMT
Release Date Price: ₹1214.2 (-0.47%)

Key Points

Positve
  • Total revenue grew by 5% to INR 1,562 crore.
  • EBITDA increased by 14% to INR 239 crore, representing 15% of sales.
  • Net profit rose by 12% to INR 135 crore.
  • India branded business grew by 9% to INR 572 crore, with strong performance in specialty therapies.
  • US business grew by 18%, with two new product launches and ten more expected in the upcoming quarter.
Negative
  • Gross borrowing increased to INR 589 crore from INR 430 crore in March '24.
  • API business underperformed, declining by 15% to INR 260 crore.
  • Excessive heatwaves in Q1 negatively impacted specific geographies.
  • US market faces double-digit pricing pressure.
  • Constraints in supply affected ROW sales, with expectations of improvement in subsequent quarters.
Operator

Ladies and gentlemen, good day, and welcome to the Q1 FY25 earnings conference call of Alembic Pharmaceuticals Limited. We have with us today Mr. Pranav Amin, Managing Director; Mr. Shaunak Amin , Managing Director; Mr. R.K. Baheti, Director, Finance and CFO; Mr. Ajay Kumar Desai, Senior VP Finance.

As a reminder, this conference call as only for analytics and institutional investors (Operator Instructions) Please note that this conference is being recorded, and I now hand the conference over to Mr. R.K. Baheti. Thank you, and over to you, sir.

R. K. Baheti
Alembic Pharmaceuticals Limited - Director - Finance & CFO

Thanks. Good evening, everyone. Thank you all for joining our first quarter results for FY24/'25. I'm sure you would have received the results. However, let me briefly take you through the numbers. During the quarter, our total revenue grew by 5% to INR 1,562 crore. EBITDA at INR 239 crore is about 15% of sales and grew by 14%. Net profit grew by 12% to INR 135 crore comparing the results corresponding quarter of last year.

Already have an account? Log in
Get the full story
Start 7-Day Free Trial
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
© 2004-2024 GuruFocus.com, LLC. All Rights Reserved.